

# Drug Eligible for Billing C9399

January 2023



Generic Name	Brand Name	FDA Approval Date	Route*	Company	Package Insert
Abaloparatide	Tymlos	4/28/2017	Subcutaneous	Radius Health	<a href="#">Tymlos PI</a>
Adalimumab-Aacf	Idacio	12/13/2022	Subcutaneous	Fresenius Kabi USA	<a href="#">Idacio PI</a>
Adalimumab-adaz	Hyrimoz	10/30/2018	Subcutaneous	Sandoz	<a href="#">Hyrimoz PI</a>
Adalimumab-adbm	Cyltezo	8/25/2017	Subcutaneous	Boehringer Ingelheim	<a href="#">Cyltezo PI</a>
Adalimumab-afzb	Abrilada	11/15/2019	Subcutaneous	Pfizer	<a href="#">Abrilada PI</a>
Adalimumab-aqvh	Yusimry	12/17/2021	Subcutaneous	Coherus Biosciences	<a href="#">Yusimry PI</a>
Adalimumab-atto	Amjevita	9/23/2016	Subcutaneous	Amgen	<a href="#">Amjevita PI</a>
Adalimumab-bwwd	Hadlima	7/23/2019	Subcutaneous	Merck, Sharp & Dohme	<a href="#">Hadlima PI</a>
Amisulpride	Barhemsys	2/26/2020	IV infusion	Acacia Pharma	<a href="#">Barhemsys PI</a>
Angiotensin-II	Giapreza	12/21/2017	IV infusion	La Jolla Pharmaceutical	<a href="#">Giapreza PI</a>
Ansuvimab-zykl	Ebanga	12/21/2020	IV infusion	Ridgeback	<a href="#">Ebanga PI</a>
Betibeglogene autotemcel	Zyntelgo	8/17/2022	IV infusion	Bluebird Bio Inc	<a href="#">Zyntelgo PI</a>
Bevacizumab-adcd	Vegzelma	9/27/2022	IV infusion	Celltrion	<a href="#">Vegzelma PI</a>
Brivaracetam injection	Briviact	2/18/2016	IV push	UCB	<a href="#">Briviact PI</a>
Bupivacaine solution for infiltration use	Posimir	2/1/2021	Infiltration	Durect Corp	<a href="#">Posimir PI</a>
Chlorprocaine	Clorotekal	9/26/2017	Intrathecal	B. Braun	<a href="#">Clorotekal PI</a>
Dantrolene (special formulation)	Ryanodex	7/22/2014	IV push	Eagle Pharmaceuticals	<a href="#">Ryanodex PI</a>
Daxibotulinumtoixna-lanm	Daxxify	9/7/2022	IM injection	Revance Therapeutics Inc	<a href="#">Daxxify PI</a>
Defibrotide	Defitelio	3/30/2016	IV infusion	Jazz Pharmaceuticals	<a href="#">Defitelio PI</a>
Desiglucon	Zegalogue	3/22/2021	Subcutaneous	Zealan Pharma A/S	<a href="#">Zegalogue PI</a>
Dinutuximab	Unituxin	3/10/2015	IV infusion	United Therapeutics	<a href="#">Unituxin PI</a>
Elapegedemase-lvlr	Revcovi	10/5/2018	Intramuscular	Leadiant Biosciences	<a href="#">Revcovi PI</a>
Eivaldogene autotemcel	Skysona	9/16/2022	IV infusion	Bluebird Bio Inc	<a href="#">Skysona PI</a>
Erenumab-aooe	Aimovig	5/17/2018	Subcutaneous	Amgen	<a href="#">Aimovig PI</a>
Etanercept-szsz	Erelzi	8/30/2016	Subcutaneous	Sandoz	<a href="#">Erelzi PI</a>
Etanercept-ykro	Eticovo***	4/25/2019	Subcutaneous	Samsung Bioepis	<a href="#">Eticovo PI</a>
Etranacogene dezaparvovec-drlb	Hemgenix	11/22/2022	IV infusion	uniQure, Inc.	<a href="#">Hemgenix PI</a>
Evolocumab	Repatha	8/27/2015	Subcutaneous	Amgen	<a href="#">Repatha PI</a>
Fosdenopterin	Nulibry	2/26/2021	IV infusion	Origin Biosciences	<a href="#">Nulibry PI</a>
Galcanezumab-gnlm	Emgality	9/27/2018	Subcutaneous	Lilly	<a href="#">Emgality PI</a>

## Drug Eligible for Billing C9399

January 2023



Generic Name	Brand Name	FDA Approval Date	Route*	Company	Package Insert
Human fibrinogen, human thrombin	Vistaseal	11/1/2019	Topical	Grifols USA	<a href="#">Vistaseal PI</a>
Idarucizumab	Praxbind	10/16/2015	IV bolus; IV infusion	Portola Pharmaceuticals	<a href="#">Praxbind PI</a>
Inotersen	Tegsedi	10/5/2018	Subcutaneous	Akcea Therapeutics	<a href="#">Tegsedi PI</a>
Insulin Glargine-Aglr	Rezvoglar	11/16/2022	Subcutaneous	Eli Lilly and Company	<a href="#">Rezvoglar PI</a>
Insulin glargine-aglr	Tezvoglar	12/17/2021	Subcutaneous; IV infusion	Lilly	<a href="#">Rezvoglar PI</a>
Insulin lispro-aabc	Lyumjev	6/15/2020	Subcutaneous; IV infusion	Lilly	<a href="#">Lyumjev PI</a>
Letermovir	Prevmis	11/8/2017	IV infusion	Merck, Sharp & Dohme	<a href="#">Prevmis PI</a>
Lonapegsomatropin-tcgd	Skytrofa	8/25/2021	Subcutaneous	Ascendis Pharma	<a href="#">Skytrofa PI</a>
Methylene Blue (for methemoglobinemia)	Provayblue	4/8/2016	IV push; IV infusion	American Regent	<a href="#">Provayblue PI</a>
Mirvetuximab Soravtansine-Gynx	Elahere	11/14/2022	IV infusion	ImmunoGen, Inc.	<a href="#">Elahere PI</a>
Obiltoximab	Anthim	3/18/2016	IV infusion	Elusys Therapeutics	<a href="#">Anthim PI</a>
Olipudase Alfa-rpcp	Xenpozyme	8/31/2022	IV infusion	Genzyme Corp	<a href="#">Xenpozyme PI</a>
Pafolacianine sodium	Cytalux	11/29/2021	IV infusion	On Target Labs	<a href="#">Cytalux PI</a>
Pasireotide injection	Signifor	12/14/2012	Subcutaneous	Novartis	<a href="#">Signifor PI</a>
Pasireotide injection	Signifor-LAR	12/15/2014	Intramuscular	Novartis	<a href="#">Signifor-LAR PI</a>
Pegcetacoplan	Empaveli	5/14/2021	Subcutaneous infusion	Apellis Pharmaceuticals	<a href="#">Empaveli PI</a>
Pegfilgrastim-fpgk	Stimufend	9/1/2022	Subcutaneous	Fresenius Kabi USA	<a href="#">Stimufend PI</a>
Pegfilgrastim-pbbk	Fylnetra	5/26/2022	Subcutaneous	Kashiv Bioscience	<a href="#">Fylnetra PI</a>
Pegvaliase-pqpz	Palynziq	5/24/2018	Subcutaneous	BioMarin Pharmaceutical	<a href="#">Palynziq PI</a>
Posaconazole injection	Noxafil	3/13/2014	IV infusion	Merck, Sharp & Dohme	<a href="#">Noxafil PI</a>
Prabotulinum Toxin A-xvfs	Jeuveau	2/1/2019	Intramuscular	Evolus	<a href="#">Jeuveau PI</a>
Ranibizumab-eqrn	Cimerli	8/2/2022	Intravitreal Injection	Coherus Biosciences	<a href="#">Cimerli PI</a>
Ropeginteron alfa-2b-njft	Besremi	11/12/2021	Subcutaneous	Pharmaeeseentia	<a href="#">Besremi PI</a>
Sarilumab	Kevzara	5/22/2017	Subcutaneous	Sanofi-Aventis	<a href="#">Kevzara PI</a>
Satralizumab	Enspryng	8/14/2020	Subcutaneous	Genentech	<a href="#">Enspryng PI</a>
Selexipag injection	Uptravi	7/29/2021	IV infusion	Actelion	<a href="#">Uptravi PI</a>
Semaglutide	Ozempic	12/5/2017	Subcutaneous	Novo Nordisk	<a href="#">Ozempic PI</a>
Semaglutide	Wegovy**	6/4/2021	Subcutaneous	Novo Nordisk	<a href="#">Wegovy PI</a>
Setmelanotide	Imcivree**	11/25/2020	Subcutaneous	Rhythm Pharm	<a href="#">Imcivree PI</a>
Sodium Thiosulfate	Pedmark	9/20/2022	IV infusion	Fennec Pharmaceuticals Inc	<a href="#">Pedmark PI</a>

## Drug Eligible for Billing C9399

January 2023



Generic Name	Brand Name	FDA Approval Date	Route*	Company	Package Insert
Somapacitan-beco	Sogroya	8/28/2020	Subcutaneous	Novo Nordisk	<a href="#">Sogroya PI</a>
Spesolimab-sbzo	Spevigo	9/1/2022	IV infusion	Boehringer Ingelheim	<a href="#">Spevigo PI</a>
Sugammadex	Bridion	12/15/2015	IV push	Merck, Sharp & Dohme	<a href="#">Bridion PI</a>
Teclistamab-Cqyv	Tecvayli	10/25/2022	Subcutaneous	Janssen Biotech, Inc	<a href="#">Tecvayli PI</a>
Tecovirimat	Tpoxx	5/18/2022	IV infusion	Siga Tech	<a href="#">Tpoxx PI</a>
Teduglutide [rDNA origin]	Gattex	12/21/2012	Subcutaneous	Shire-NPS Pharma	<a href="#">Gattex PI</a>
Teplizumab-Mzww	Tzield	11/17/2022	IV infusion	Provention Bio, Inc.	<a href="#">Tzield PI</a>
Terlipressin	Terlivaz	9/14/2022	IV bolus injection	Mallinckrodt	<a href="#">Terlivaz PI</a>
Tirzepatide	Mounjaro	5/13/2022	Subcutaneous	Lilly	<a href="#">Mounjaro PI</a>
Tralokinumab-ldrm	Adbry	12/27/2021	Subcutaneous	Leo Pharma AS	<a href="#">Adbry PI</a>
Tremelimumab-Actl	Imjudo	10/21/2022	IV infusion	AstraZeneca Pharmaceuticals LP	<a href="#">Imjudo PI</a>
Ublituximab	Briumvi	12/28/2022	IV infusion	TG Therapeutics, Inc	<a href="#">Briumvi PI</a>
Vosorotide	Voxzogo	11/19/2021	Subcutaneous	BioMarin Pharmaceutical	<a href="#">Voxzogo PI</a>

\*Note some payers may cover subcutaneous injections under a Pharmacy benefit rather than the Medical benefit

\*\* Must be administered by a healthcare professional

Updated: 01/03/2023

The Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.